Barriers to preexposure prophylaxis use among individuals with recently acquired HIV infection in Northern California.


Journal

AIDS care
ISSN: 1360-0451
Titre abrégé: AIDS Care
Pays: England
ID NLM: 8915313

Informations de publication

Date de publication:
05 2019
Historique:
pubmed: 12 10 2018
medline: 7 1 2020
entrez: 12 10 2018
Statut: ppublish

Résumé

Barriers to HIV preexposure prophylaxis (PrEP) use have not been well-characterized in people who became HIV-infected, all of whom could have benefited from PrEP. We invited Kaiser Permanente Northern California members diagnosed with HIV during 2014-2016, following a negative HIV test in the prior year, to complete a survey assessing barriers to PrEP use before HIV diagnosis. Of 268 patients surveyed, 122 (46%) responded. Median age was 36, most (84%) were men who have sex with men, and 64% were of minority racial/ethnic background. Thirty-six (30%) had discussed PrEP with a provider, of whom 10 were diagnosed with HIV at PrEP intake. Overall, only 5 (4.1%) had used PrEP, and all 5 discontinued before diagnosis. Among all respondents, the most common barrier to PrEP use was lack of PrEP awareness (51%). Among those aware of PrEP, the most common barriers were cost/insurance concerns (36%) and perceived low risk for HIV (24%). Lack of PrEP awareness ranged from 39% among those aged 25-34 to 88% among those aged <25 (P = 0.011), and from 33% among Hispanics to 69% among Blacks (P = 0.055). Increasing awareness and affordability of PrEP, and facilitating accurate assessment of HIV risk, are critical to reducing missed opportunities for PrEP.

Identifiants

pubmed: 30304942
doi: 10.1080/09540121.2018.1533238
pmc: PMC6408235
mid: NIHMS1510005
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

536-544

Subventions

Organisme : NIAID NIH HHS
ID : K01 AI122853
Pays : United States

Références

AIDS Behav. 2017 May;21(5):1256-1267
pubmed: 27885552
AIDS Behav. 2018 Nov;22(11):3550-3565
pubmed: 29344740
AIDS Behav. 2018 Nov;22(11):3576-3587
pubmed: 29468493
Sex Transm Dis. 2016 Nov;43(11):717-723
pubmed: 27893604
AIDS Behav. 2018 Nov;22(11):3627-3636
pubmed: 29589137
Clin Infect Dis. 2017 Jan 15;64(2):144-149
pubmed: 27986691
PLoS One. 2017 Feb 21;12(2):e0172354
pubmed: 28222118
AIDS Patient Care STDS. 2017 Dec;31(12):517-527
pubmed: 29211513
Clin Infect Dis. 2018 Jan 6;66(1):149-153
pubmed: 29020316
AIDS Care. 2018 Jan;30(1):9-17
pubmed: 28791876
Int J STD AIDS. 2017 Aug;28(9):849-857
pubmed: 28632468
AIDS Care. 2016 Nov;28(11):1378-85
pubmed: 27136725
Am J Public Health. 2016 Oct;106(10):e2-3
pubmed: 27626355
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
Prev Sci. 2017 Jul;18(5):505-516
pubmed: 28101813
MMWR Morb Mortal Wkly Rep. 2015 Nov 27;64(46):1291-5
pubmed: 26606148
J Adolesc Health. 2017 May;60(5):549-555
pubmed: 28132744
AIDS Behav. 2016 Jul;20(7):1435-42
pubmed: 26966013
Clin Infect Dis. 2015 Nov 15;61(10):1601-3
pubmed: 26334052
J Acquir Immune Defic Syndr. 2017 Jul 1;75 Suppl 3:S375-S382
pubmed: 28604442
J AIDS Clin Res. 2017 Sep;8(9):
pubmed: 29201531
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
AIDS Educ Prev. 2017 Aug;29(4):315-329
pubmed: 28825858
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):540-546
pubmed: 27851714
J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):132-140
pubmed: 28902677
AIDS Care. 2017 Nov;29(11):1351-1358
pubmed: 28286983
Harm Reduct J. 2017 Jun 29;14(1):40
pubmed: 28662716
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
Clin Infect Dis. 2018 Aug 31;67(6):965-970
pubmed: 29635415
AIDS Behav. 2018 Nov;22(11):3566-3575
pubmed: 29404756
AIDS Behav. 2018 Jun;22(6):1932-1943
pubmed: 29103191

Auteurs

Julia L Marcus (JL)

a Harvard Medical School and Harvard Pilgrim Health Care Institute , Boston , MA , USA.

Leo B Hurley (LB)

b Kaiser Permanente Division of Research , Oakland , CA , USA.

Dennis Dentoni-Lasofsky (D)

c Kaiser Permanente Oakland Medical Center , Oakland , CA , USA.

Courtney G Ellis (CG)

b Kaiser Permanente Division of Research , Oakland , CA , USA.

Michael J Silverberg (MJ)

b Kaiser Permanente Division of Research , Oakland , CA , USA.

Sally Slome (S)

c Kaiser Permanente Oakland Medical Center , Oakland , CA , USA.

Jonathan M Snowden (JM)

d Oregon Health & Science University-Portland State University , Portland , OR , USA.

Jonathan E Volk (JE)

e Kaiser Permanente San Francisco Medical Center , San Francisco , CA , USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH